WHAT IS CLAIMED IS:

1. Use of a chelate complex of at least one phosphorothioated nucleic acid polymer; and at least one nucleoside / nucleotide analog HBV polymerase inhibitor in the manufacture of a medicament for treating HBV infection or HBV / HDV co-infection in a subject in the absence of immunotherapy.

2. Use of a chelate complex of one or more nucleic acid polymers selected from the following:

SEQ ID NO: 2;
SEQ ID NO: 10;
SEQ ID NO 13;
SEQ ID NOs: 1, 3-9, 11, 12 and 14-20;
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence AC;
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence CA;
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence TG and
a phosphorothioated oligonucleotide from 20- 120 nucleotides in length comprising repeats of the sequence GT;

and at least one nucleoside / nucleotide analog HBV polymerase inhibitor selected from the following:

lamivudine;
adefovir dipivoxil;
entecavir;
telbivudine;
tenofovir disoproxil fumarate;
entricitabine;
clevudine;
besifovir;
tenofovir alafenamide fumarate;
AGX-1009;
elvucitabine;
lagociclovir valactate;

pradefovir mesylate;

valtorcitabine; and

any nucleoside / nucleotide analog which inhibits the HBV polymerase,

in the manufacture of a medicament for the treatment of HBV infection or HBV/HDV co-infection in the absence of immunotherapy.

3. The use of any one of claims 1-2, wherein the nucleic acid polymer further comprises at least one 2' ribose modification.

4. The use of any one of claims 1-3, wherein the nucleic acid polymer further comprises all riboses having a 2' modification.

5. The use of any one of claims 1-4, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification.

6. The use of any one of claims 1-5, wherein the nucleic acid polymer further comprises all riboses having a 2' O methyl modification.

7. The use of any one of claims 1-6, wherein the nucleic acid polymer further comprises at least one 5'methylcytosine.

8. The use of any one of claims 1-7, wherein the nucleic acid polymer further comprises all cytosines present as 5'methylcytosine.

9. The use of any one of claims 1-8, wherein the nucleic acid polymer further comprises at least one 2' O methyl ribose modification and at least one 5'methylcytosine.

10. The use of any one of claims 1-9, wherein the nucleic acid polymer further comprises all riboses having the 2' O methyl modification and all cytosines present as 5'methylcytosine.

11. The use of any one of claims 1-10, wherein the chelate complex is a calcium chelate complex.

12. The use of any one of claims 1-10, wherein the chelate complex is a magnesium chelate complex.

13. The use of any one of claims 1-10, wherein the chelate complex is a calcium / magnesium chelate complex.

14. The use of any one of claims 1-13, wherein said first and second pharmaceutically acceptable agents are formulated within the same pharmaceutical composition.

15. The use of any one of claims 1-13, wherein said first and second agents are formulated within separate pharmaceutical compositions.

16. The use of any one of claims 1-13, wherein said first and second agents are formulated for a simultaneous administration.

17. The use of any one of claims 1-13, wherein said first and second agents are formulated for an administration by a different route.

18. The use of any one of claims 1-17, wherein said first and second agents are formulated for an administration using one or more of the following: oral ingestion, aerosol inhalation, subcutaneous injection, intravenous injection and intravenous infusion.